FluGen Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Employees
  • 17
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $19.3M
Latest Deal Amount
  • Investors
  • 9

FluGen General Information

Description

Developer of vaccines intended to prevent influenza and other respiratory pathogens such as COVID-19. The company's vaccines focus on the prevention of both seasonal and pandemic influenza with a live, single replication, intranasally delivered virus which has a portion of the M2 segment deleted (M2SR). enabling healthcare professionals to prevent the spreading of influenza.

Contact Information

Website
www.flugen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 597 Science Drive
  • Madison, WI 53711
  • United States
+1 (608) 000-0000

FluGen Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

FluGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A) 01-May-2020 $19.3M 0000 000.00 Completed Clinical Trials - Phase 1
5. Grant 14-Sep-2017 0000 000.00 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series A) 14-Apr-2017 000 000.00 000.00 Completed Clinical Trials - General
3. Later Stage VC (Series A) 20-Aug-2015 000.00 000.00 000.00 Completed Clinical Trials - General
2. Debt - General 02-Jun-2014 $3.4M $5.57M Completed Clinical Trials - General
1. Angel (individual) 31-Dec-2007 $2.17M $2.17M Completed Startup
To view FluGen’s complete valuation and funding history, request access »

FluGen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view FluGen’s complete cap table history, request access »

FluGen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of vaccines intended to prevent influenza and other respiratory pathogens such as COVID-19. The company's vacc
Drug Discovery
Madison, WI
17 As of 2020
0000
00.00 0000-00-00
00000000000 0000

000000 0

niam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute i
0000 000000000
New York, NY
00 As of 0000
000.00
000000 - 000 000.00

00000000

prehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
000000000000000
South San Francisco, CA
00 As of 0000
00000
0000000000.
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

FluGen Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anavex Life Sciences Corporation New York, NY 00 000.00 000000 - 000 000.00
00000000 Formerly VC-backed South San Francisco, CA 00 00000 0000000000.
000000000 00000000 Corporation Pasadena, CA 000 00.000 000000 - 000 00.000
00000 000000000000 Formerly VC-backed San Francisco, CA 00 00000 000000&0 00000
000 00000000(00000 Corporation Cambridge, MA 000 000.00 00000000 000.00
You’re viewing 5 of 35 competitors. Get the full list »

FluGen Executive Team (7)

Name Title Board Seat Contact Info
Paul Radspinner Co-Founder, Chief Executive Officer, President & Board Member
Pamuk Bilsel Ph.D Chief Scientific Officer
Andy Skibo Ph.D Chief Manufacturing Officer
Gabriele Neumann Ph.D Co-Founder
Renee Herber Vice President, Research & Development Operations
You’re viewing 5 of 7 executive team members. Get the full list »

FluGen Board Members (19)

Name Representing Role Since
Boyd Clarke Self Chairman 000 0000
David Newberg Knox Board Member 000 0000
David Walsh JD Self Board Member 000 0000
Eric Patzer Ph.D Self Board Member 000 0000
Erik Iverson JD Wisconsin Alumni Research Foundation Board Member 000 0000
You’re viewing 5 of 19 board members. Get the full list »

FluGen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

FluGen Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bryan Renk Angel (individual) Minority 000 0000 000000 0
Internal Revenue Service Government 000 0000 000000 0
Small Business Innovation Research and Small Business Technology Transfer Programs Government 000 0000 000000 0
United States Department of Defense Government 000 0000 000000 0
Knox Angel Group Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »